» Articles » PMID: 35625682

PNC-27, a Chimeric P53-Penetratin Peptide Binds to HDM-2 in a P53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis

Abstract

PNC-27, a 32-residue peptide that contains an HDM-2 binding domain and a cell-penetrating peptide (CPP) leader sequence kills cancer, but not normal, cells by binding to HDM-2 associated with the plasma membrane and induces the formation of pores causing tumor cell lysis and necrosis. Conformational energy calculations on the structure of PNC-27 bound to HDM-2 suggest that 1:1 complexes form between PNC-27 and HDM-2 with the leader sequence pointing away from the complex. Immuno-scanning electron microscopy was carried out with cancer cells treated with PNC-27 and decorated with an anti-PNC-27 antibody coupled to 6 nm gold particles and an anti-HDM-2 antibody linked to 15 nm gold particles. We found multiple 6 nm- and 15 nm-labeled gold particles in approximately 1:1 ratios in layered ring-shaped structures in the pores near the cell surface suggesting that these complexes are important to the pore structure. No pores formed in the control, PNC-27-treated untransformed fibroblasts. Based on the theoretical and immuno-EM studies, we propose that the pores are lined by PNC-27 bound to HDM-2 at the membrane surface with the PNC-27 leader sequence lining the pores or by PNC-27 bound to HDM-2.

Citing Articles

Phage libraries screening on P53: Yield improvement by zinc and a new parasites-integrating analysis.

Ben Abid S, Ketata E, Yacoubi I, Djemal L, Abdelmoula-Souissi S, Koubaa A PLoS One. 2024; 19(10):e0297338.

PMID: 39361673 PMC: 11449285. DOI: 10.1371/journal.pone.0297338.


Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells.

Pincus M, Silberstein M, Zohar N, Sarafraz-Yazdi E, Bowne W Biomedicines. 2024; 12(6).

PMID: 38927351 PMC: 11201261. DOI: 10.3390/biomedicines12061144.


Ketone Bodies Induce Unique Inhibition of Tumor Cell Proliferation and Enhance the Efficacy of Anti-Cancer Agents.

Miller A, Diaz D, Lin B, Krzesaj P, Ustoyev S, Shim A Biomedicines. 2023; 11(9).

PMID: 37760956 PMC: 10526402. DOI: 10.3390/biomedicines11092515.


Recent advances and applications of peptide-agent conjugates for targeting tumor cells.

Alamdari-Palangi V, Rahimi Jaberi K, Shahverdi M, Naeimzadeh Y, Tajbakhsh A, Khajeh S J Cancer Res Clin Oncol. 2023; 149(16):15249-15273.

PMID: 37581648 DOI: 10.1007/s00432-023-05144-9.


Peptides That Block RAS-p21 Protein-Induced Cell Transformation.

Pincus M, Lin B, Patel P, Gabutan E, Zohar N, Bowne W Biomedicines. 2023; 11(2).

PMID: 36831007 PMC: 9953342. DOI: 10.3390/biomedicines11020471.


References
1.
Bowne W, Sookraj K, Vishnevetsky M, Adler V, Sarafraz-Yazdi E, Lou S . The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol. 2008; 15(12):3588-600. DOI: 10.1245/s10434-008-0147-0. View

2.
Wang H, Zhao D, Nguyen L, Wu H, Li L, Dong D . Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia. 2019; 34(1):75-86. PMC: 7951797. DOI: 10.1038/s41375-019-0522-9. View

3.
Kanovsky M, Raffo A, Drew L, Rosal R, Do T, Friedman F . Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci U S A. 2001; 98(22):12438-43. PMC: 60072. DOI: 10.1073/pnas.211280698. View

4.
Dathe M, Wieprecht T . Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim Biophys Acta. 1999; 1462(1-2):71-87. DOI: 10.1016/s0005-2736(99)00201-1. View

5.
Tilley S, Orlova E, Gilbert R, Andrew P, Saibil H . Structural basis of pore formation by the bacterial toxin pneumolysin. Cell. 2005; 121(2):247-56. DOI: 10.1016/j.cell.2005.02.033. View